Phase III study shows everolimus delays tumour progression in hard-to-treat neuroendocrine tumours
Wednesday, October 13, 2010 - 10:02
in Health & Medicine
The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumour progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells...